Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LAB

Standard BioTools Inc

May 02 • 04:00PM ET

2.53

Dollar change -0.01
Percentage change -0.39	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKG VTI VXF VHT IWC DFAC ITOT FHLC DFAT AVUS

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	3.54%	Shs Outstand	383.05M	Perf Week	7.20%
Market Cap	969.12M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	1.89%	Shs Float	369.48M	Perf Month	-4.89%
Income	-74.66M	PEG	-	EPS next Q	-0.11	Inst Own	54.49%	Short Float	3.05%	Perf Quarter	10.48%
Sales	106.34M	P/S	9.11	EPS this Y	62.14%	Inst Trans	-1.53%	Short Ratio	5.02	Perf Half Y	27.14%
Book/sh	-1.85	P/B	-	EPS next Y	48.37%	ROA	-20.93%	Short Interest	11.28M	Perf Year	72.11%
Cash/sh	0.30	P/C	8.44	EPS next 5Y	-	ROE	-37.99%	52W Range	1.46 - 3.16	Perf YTD	14.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.72%	ROI	-37.79%	52W High	-19.94%	Beta	1.67
Dividend TTM	-	Quick Ratio	1.26	Sales past 5Y	-0.06%	Gross Margin	47.24%	52W Low	73.29%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	1.45	EPS Y/Y TTM	61.39%	Oper. Margin	-60.36%	RSI (14)	46.36	Volatility	4.47% 6.00%
Employees	539	Debt/Eq	0.60	Sales Y/Y TTM	8.57%	Profit Margin	-70.21%	Recom	1.00	Target Price	3.58
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	5.49%	Payout	-	Rel Volume	0.76	Prev Close	2.54
Sales Surprise	13.20%	EPS Surprise	-4.17%	Sales Q/Q	4.32%	Earnings	May 08 AMC	Avg Volume	2.25M	Price	2.53
SMA20	-3.98%	SMA50	-2.80%	SMA200	4.29%	Trades		Volume	1,714,294	Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Initiated	TD Cowen	Buy	$3.50
Apr-04-24	Initiated	Jefferies	Buy	$3.25
Jul-12-23	Initiated	KeyBanc Capital Markets	Overweight	$4

Apr-25-24 11:27AM	Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction (MT Newswires)
08:01AM	Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth (GlobeNewswire)
08:00AM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging (GlobeNewswire) +5.11%
Apr-03-24 04:01PM	Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research (GlobeNewswire)
08:12AM	Loading…
Mar-18-24 08:12AM	Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock (GlobeNewswire)
Mar-05-24 08:27AM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:29AM	Q4 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) -5.06%
Feb-28-24 04:41PM	Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ... (GuruFocus.com)
04:16PM	Standard BioTools: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing (GlobeNewswire)
Feb-22-24 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-24 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-07-24 08:30AM	Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine (GlobeNewswire)
08:30AM	Loading…
Jan-08-24 08:30AM	Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue (GlobeNewswire) +13.37%
Jan-05-24 08:46AM	Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools (GlobeNewswire)
Jan-04-24 10:23PM	Standard BioTools Stockholders Approve Merger with SomaLogic (GlobeNewswire) -5.39%
09:44PM	SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting (PR Newswire)
Dec-29-23 05:04PM	Glass Lewis Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-28-23 04:16PM	Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools (PR Newswire) +5.45%
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire) +7.54%
Dec-22-23 06:57PM	ISS Recommends Standard BioTools Stockholders Vote FOR All Proposals Relating to Proposed Merger with SomaLogic (GlobeNewswire)
Dec-21-23 08:00AM	SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools (GlobeNewswire)
Dec-20-23 09:00AM	Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools (GlobeNewswire) -8.10%
Dec-17-23 03:37PM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-12-23 04:32PM	SomaLogic Shareholder Madryn Opposes Standard BioTools Merger (Bloomberg)
Dec-11-23 10:37AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-06-23 11:18AM	Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC) (GlobeNewswire)
Dec-04-23 08:00AM	Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger (GlobeNewswire)
05:54AM	Loading…
Nov-09-23 05:54AM	Q3 2023 Somalogic Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
Nov-08-23 12:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:52AM	Q3 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:23PM	Standard BioTools: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:30AM	Standard BioTools to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-25-23 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire) -10.50%
Oct-10-23 10:22AM	Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm (GlobeNewswire)
Oct-05-23 02:42PM	Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm (PR Newswire)
Oct-04-23 06:49PM	Why SomaLogic Stock Dived by 10% on Wednesday (Motley Fool) -22.22%
08:52AM	Standard BioTools to Combine with SomaLogic in $1 Billion Merger (Bloomberg)
08:00AM	Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools (GlobeNewswire)
Aug-09-23 09:06AM	Q2 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents) +7.56%
Aug-08-23 05:36PM	Standard BioTools: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Standard BioTools Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-25-23 04:05PM	Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 07:33AM	Strong week for Standard BioTools (NASDAQ:LAB) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
Jun-14-23 07:30AM	Standard BioTools to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-13-23 01:30PM	With 45% ownership, Standard BioTools Inc. (NASDAQ:LAB) has piqued the interest of institutional investors (Simply Wall St.)
May-25-23 04:05PM	Standard BioTools to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:11AM	With Standard BioTools Up 29%, Insider Buyers Count Their Returns \ (Simply Wall St.)
06:05AM	Jeffrey Black Spends US$194k On Standard BioTools Stock \ (Simply Wall St.)
May-18-23 07:30AM	Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System (GlobeNewswire) +12.05%
May-15-23 07:30AM	Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
May-10-23 02:47PM	Standard BioTools Inc. (NASDAQ:LAB) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.85%
06:16AM	Q1 2023 Standard BioTools Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 06:11PM	Standard BioTools: Q1 Earnings Snapshot (AP Finance)
04:05PM	Standard BioTools Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-25-23 04:30PM	Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-20-23 05:03PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-23 10:42AM	Standard BioTools Inc.'s (NASDAQ:LAB) Low P/S No Reason For Excitement (Simply Wall St.)
Apr-17-23 08:30AM	Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology (GlobeNewswire)
Mar-22-23 08:30AM	Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-23 08:30AM	Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors (GlobeNewswire)
Mar-14-23 08:30AM	Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire) +11.05%
Mar-01-23 04:05PM	Standard BioTools to Present at 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-23 08:30AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-17-23 06:43PM	Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-15-23 06:01PM	How a Peninsula biotech tools company looks to corral 'one-trick ponies' (American City Business Journals)
Feb-14-23 04:05PM	Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook (GlobeNewswire)
Feb-03-23 05:30AM	The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable (Simply Wall St.)
Jan-31-23 08:30AM	Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Jan-09-23 08:30AM	Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update (GlobeNewswire) +6.45%
Jan-03-23 08:30AM	Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer (GlobeNewswire) +11.11%
Dec-24-22 08:01AM	Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year (Simply Wall St.)
Nov-28-22 08:30AM	Standard BioTools Authorizes up to $20 Million of Share Repurchases (GlobeNewswire) +10.00%
Nov-22-22 09:20AM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-22 05:02AM	Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) (Simply Wall St.) +26.42%
Nov-08-22 04:05PM	Standard BioTools Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems (GlobeNewswire) -9.82%
Oct-25-22 08:30AM	Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results (GlobeNewswire) +14.95%
Oct-13-22 08:30AM	Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China (GlobeNewswire)
Oct-06-22 08:30AM	Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform (GlobeNewswire)
Aug-25-22 04:05PM	Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-22 10:38AM	Is Standard BioTools (NASDAQ:LAB) Using Debt In A Risky Way? (Simply Wall St.)
Aug-08-22 04:02PM	Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update (GlobeNewswire) +7.94%
Jul-25-22 04:30PM	Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results (GlobeNewswire) -6.80%
Jul-04-22 11:56AM	Shareholders in Standard BioTools (NASDAQ:LAB) have lost 86%, as stock drops 12% this past week (Simply Wall St.)
May-05-22 04:02PM	Standard BioTools Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-22-22 04:02PM	Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results (GlobeNewswire)
Apr-11-22 08:30AM	Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging (GlobeNewswire)
Apr-05-22 07:30AM	Labrador Gold Intersects 6.07 g/t Au Over 19 Metres at the Big Vein Target, Kingsway Property (GlobeNewswire) -7.02%
Mar-29-22 08:00AM	Labrador Gold Extends High-Grade Gold Mineralization to 250m Southwest of Big Vein Discovery (GlobeNewswire) +10.61%

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Egholm Michael	President & CEO	Apr 04 '24	Option Exercise	0.00	196,512	0	422,030	Apr 05 06:59 PM
Kim Hanjoon Alex	Chief Operating Officer	Apr 04 '24	Option Exercise	0.00	70,183	0	140,366	Apr 05 06:58 PM
Casdin Partners Master Fund, L	Director	Mar 05 '24	Buy	2.62	1,403	3,669	11,497,928	Mar 06 07:20 PM
Casdin Partners Master Fund, L	Director	Mar 04 '24	Buy	2.57	250,000	642,500	11,496,525	Mar 06 07:20 PM
Casdin Eli	Director	May 19 '23	Buy	2.29	800,000	1,835,920	1,200,000	May 19 09:02 PM
Casdin Partners Master Fund, L	Director	May 19 '23	Buy	2.29	800,000	1,835,920	1,200,000	May 19 09:00 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 19 '23	Buy	2.29	42,492	97,213	85,984	May 22 06:49 PM
Casdin Eli	Director	May 18 '23	Buy	2.16	150,000	323,865	400,000	May 19 09:02 PM
Casdin Partners Master Fund, L	Director	May 18 '23	Buy	2.16	150,000	323,865	400,000	May 19 09:00 PM
Black Jeffrey G.	SVP & Chief Financial Officer	May 18 '23	Buy	2.22	43,492	96,365	43,492	May 22 06:49 PM
Casdin Eli	Director	May 17 '23	Buy	1.89	250,000	471,550	250,000	May 19 09:02 PM
Casdin Partners Master Fund, L	Director	May 17 '23	Buy	1.89	250,000	471,550	250,000	May 19 09:00 PM

Open in Screener

TVTX

Travere Therapeutics Inc

May 02 • 04:00PM ET

6.16

Dollar change +0.16
Percentage change 2.67	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TVTX Travere Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB LABU VTWO SCHA VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-4.56	Insider Own	1.41%	Shs Outstand	75.37M	Perf Week	14.29%
Market Cap	468.78M	Forward P/E	-	EPS next Y	-1.85	Insider Trans	-5.26%	Shs Float	75.03M	Perf Month	-11.75%
Income	-337.40M	PEG	-	EPS next Q	-0.94	Inst Own	113.82%	Short Float	15.73%	Perf Quarter	-28.37%
Sales	198.84M	P/S	2.36	EPS this Y	-94.39%	Inst Trans	0.10%	Short Ratio	9.66	Perf Half Y	-4.94%
Book/sh	2.66	P/B	2.31	EPS next Y	36.70%	ROA	-47.87%	Short Interest	11.80M	Perf Year	-60.64%
Cash/sh	7.45	P/C	0.83	EPS next 5Y	-	ROE	-287.12%	52W Range	5.12 - 19.54	Perf YTD	-31.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.34%	ROI	-56.17%	52W High	-68.48%	Beta	0.70
Dividend TTM	-	Quick Ratio	3.41	Sales past 5Y	3.07%	Gross Margin	69.95%	52W Low	20.31%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	3.47	EPS Y/Y TTM	-4.33%	Oper. Margin	-171.72%	RSI (14)	46.70	Volatility	7.81% 6.10%
Employees	380	Debt/Eq	2.02	Sales Y/Y TTM	-6.21%	Profit Margin	-169.68%	Recom	1.69	Target Price	15.00
Option/Short	Yes / Yes	LT Debt/Eq	1.99	EPS Q/Q	-15.12%	Payout	-	Rel Volume	0.67	Prev Close	6.00
Sales Surprise	8.08%	EPS Surprise	-1.94%	Sales Q/Q	-19.35%	Earnings	May 06 AMC	Avg Volume	1.22M	Price	6.16
SMA20	0.82%	SMA50	-13.70%	SMA200	-33.45%	Trades		Volume	823,572	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22
Dec-05-22	Initiated	Wells Fargo	Overweight	$28
Sep-21-22	Initiated	Bryan Garnier	Sell	$17
Jul-14-22	Resumed	Canaccord Genuity	Buy	$49 → $42
Mar-31-22	Initiated	Piper Sandler	Overweight	$42
Feb-28-22	Initiated	H.C. Wainwright	Buy	$45
May-26-21	Downgrade	Wedbush	Outperform → Neutral	$19

Show Previous Ratings

Apr-29-24 04:30PM	Travere Therapeutics to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 07:05AM	Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (GlobeNewswire) -5.05%
03:00AM	CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Apr-04-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International (GlobeNewswire)
Apr-03-24 04:30PM	Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association (GlobeNewswire)
05:00PM	Loading…
Mar-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.16%
Mar-11-24 07:05AM	Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire) -7.74%
Feb-26-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 07:05AM	Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy (GlobeNewswire)
02:00AM	CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy (PR Newswire)
Feb-16-24 09:52AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.18%
Feb-15-24 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +5.94%
Feb-08-24 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-01-24 04:30PM	Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-25-24 04:05PM	Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations (GlobeNewswire)
07:00AM	Loading…
Jan-08-24 07:00AM	Travere Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire) +13.66%
Jan-02-24 04:30PM	Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.34%
Dec-14-23 07:30AM	Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) (GlobeNewswire)
Dec-04-23 04:05PM	Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS (GlobeNewswire)
Nov-21-23 04:30PM	Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-09-23 06:26PM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript (Insider Monkey) -14.06%
Nov-07-23 04:01PM	Travere Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire) +8.13%
Nov-03-23 10:46AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire) +5.93%
Oct-24-23 04:30PM	Travere Therapeutics to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-13-23 04:30PM	Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire)
Oct-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 04:30PM	Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) (GlobeNewswire) +5.96%
Sep-22-23 09:38AM	Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls (The Fly)
Sep-21-23 07:30AM	Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan (GlobeNewswire) -40.68%
Sep-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:30AM	Loading…
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-31-23 04:30PM	Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference (GlobeNewswire) +8.26%
Aug-24-23 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (GlobeNewswire)
Aug-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 06:03AM	News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts (Simply Wall St.)
Aug-03-23 04:01PM	Travere Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 12:28PM	J.P. Morgan Recommends These 2 Strong Buy Stocks Including One With 90% Upside Potential (TipRanks)
Jul-20-23 04:30PM	Travere Therapeutics to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-08-23 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 (GlobeNewswire) -7.39%
Jun-01-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 07:00AM	Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria (GlobeNewswire) +9.02%
May-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-23 04:01PM	Travere Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-01-23 04:05PM	Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (GlobeNewswire)
Apr-26-23 04:30PM	Travere Therapeutics to Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-23 04:30AM	Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 (GlobeNewswire)
Mar-28-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 (GlobeNewswire)
Mar-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 (GlobeNewswire)
Mar-03-23 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-28-23 10:36PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Feb-27-23 04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-25-23 07:35AM	Travere Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Feb-23-23 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-17-23 06:30PM	Ligands Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Business Wire) -12.22%
04:04PM	Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (GlobeNewswire)
04:04PM	Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (GlobeNewswire)
Feb-16-23 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-08-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-12-23 07:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 07:00AM	Travere Therapeutics Provides Corporate Update and 2023 Outlook (GlobeNewswire)
Jan-03-23 04:30PM	Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-16-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 08:00AM	Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease (GlobeNewswire)
Nov-09-22 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-27-22 04:01PM	Travere Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 04:30PM	Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022 (GlobeNewswire)
Oct-20-22 04:30PM	Travere Therapeutics to Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-13-22 04:05PM	Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy (GlobeNewswire)
Oct-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-22 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium (GlobeNewswire)
Aug-22-22 07:00AM	Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
Aug-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-04-22 07:00AM	Travere Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +7.46%
Aug-03-22 04:05PM	Travere Therapeutics Provides Regulatory Updates on its Development Programs (GlobeNewswire)
Jul-28-22 04:30PM	Travere Therapeutics to Report Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-20-22 09:18AM	Health Check: How Prudently Does Travere Therapeutics (NASDAQ:TVTX) Use Debt? (Simply Wall St.)
Jun-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-22 04:30PM	Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress (GlobeNewswire) +9.09%
May-16-22 04:09PM	Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug (Investor's Business Daily) +6.13%
07:00AM	Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
May-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-05-22 04:01PM	Travere Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -5.09%
May-03-22 04:30PM	Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-28-22 04:30PM	Travere Therapeutics to Report First Quarter 2022 Financial Results (GlobeNewswire)
Apr-20-22 04:30PM	Travere Therapeutics Announces Plan for Chief Financial Officer Transition (GlobeNewswire)
Apr-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-11-22 08:08AM	Travere Therapeutics' (NASDAQ:TVTX) growing losses don't faze investors as the stock ascends 5.1% this past week (Simply Wall St.)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '24	Sale	6.74	54	364	70,849	Apr 12 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	8.70	19,122	166,435	350,600	Feb 02 04:06 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 01 '24	Sale	8.71	4,764	41,495	76,270	Feb 02 04:05 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 01 '24	Sale	8.71	4,764	41,495	80,720	Feb 02 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 01 '24	Sale	8.53	4,195	35,789	99,503	Feb 02 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	8.53	3,818	32,573	70,903	Feb 02 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 01 '24	Sale	8.53	2,820	24,058	52,017	Feb 02 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	8.53	2,174	18,547	58,074	Feb 02 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Sale	8.96	7,873	70,542	234,722	Jan 25 04:10 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Jan 23 '24	Sale	8.96	2,062	18,476	60,484	Jan 25 04:10 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Jan 23 '24	Sale	8.96	2,062	18,476	56,034	Jan 25 04:10 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Jan 23 '24	Sale	9.07	1,559	14,138	78,698	Jan 25 04:10 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Jan 23 '24	Sale	9.07	910	8,252	41,337	Jan 25 04:10 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Jan 23 '24	Sale	9.07	853	7,735	49,721	Jan 25 04:10 PM
Inrig Jula	Chief Medical Officer	Jan 04 '24	Sale	9.17	440	4,035	35,248	Jan 05 04:11 PM
Inrig Jula	Chief Medical Officer	Jan 03 '24	Sale	9.48	2,069	19,613	35,688	Jan 05 04:11 PM
Heerma Peter	Chief Commercial Officer	Oct 03 '23	Sale	8.25	3,091	25,504	80,257	Oct 04 04:05 PM
Dube Eric M	Chief Executive Officer	Sep 05 '23	Sale	14.71	4,455	65,533	242,595	Sep 05 08:10 PM
ROTE WILLIAM E.	Senior Vice President, R&D	Sep 05 '23	Sale	14.71	1,815	26,699	61,173	Sep 05 08:13 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	Sep 05 '23	Sale	14.71	1,815	26,699	58,096	Sep 05 08:12 PM
Cline Christopher R.	Chief Financial Officer	Sep 05 '23	Sale	14.71	457	6,723	50,574	Sep 05 08:15 PM
Calvin Sandra	SVP, Chief Accounting Officer	May 11 '23	Sale	16.12	122	1,967	42,247	May 12 04:06 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	May 10 '23	Sale	16.59	825	13,687	56,611	May 12 04:11 PM
ROTE WILLIAM E.	Senior Vice President, R&D	May 10 '23	Sale	16.59	825	13,687	59,211	May 12 04:09 PM
Cline Christopher R.	Chief Financial Officer	May 10 '23	Sale	16.59	455	7,548	51,031	May 12 04:14 PM
Calvin Sandra	SVP, Chief Accounting Officer	May 10 '23	Sale	16.59	436	7,233	42,369	May 12 04:06 PM

Open in Screener

GNSS

Genasys Inc

May 02 • 04:00PM ET

2.34

Dollar change +0.19
Percentage change 8.84	%

Technology • Scientific & Technical Instruments • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.56	Insider Own	16.06%	Shs Outstand	37.21M	Perf Week	10.38%
Market Cap	103.03M	Forward P/E	13.97	EPS next Y	0.17	Insider Trans	0.54%	Shs Float	36.96M	Perf Month	-4.49%
Income	-21.61M	PEG	-	EPS next Q	-0.13	Inst Own	40.36%	Short Float	0.46%	Perf Quarter	51.95%
Sales	40.54M	P/S	2.54	EPS this Y	13.33%	Inst Trans	-1.43%	Short Ratio	1.79	Perf Half Y	31.46%
Book/sh	0.92	P/B	2.54	EPS next Y	164.42%	ROA	-35.69%	Short Interest	0.17M	Perf Year	-20.68%
Cash/sh	0.31	P/C	7.60	EPS next 5Y	15.00%	ROE	-49.03%	52W Range	1.51 - 3.92	Perf YTD	15.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-33.99%	ROI	-48.48%	52W High	-40.30%	Beta	0.54
Dividend TTM	-	Quick Ratio	1.74	Sales past 5Y	13.50%	Gross Margin	45.41%	52W Low	54.97%	ATR (14)	0.14
Dividend Ex-Date	Jun 13, 2016	Current Ratio	2.34	EPS Y/Y TTM	-10.38%	Oper. Margin	-36.33%	RSI (14)	60.78	Volatility	6.84% 6.93%
Employees	187	Debt/Eq	0.12	Sales Y/Y TTM	-24.72%	Profit Margin	-53.31%	Recom	1.00	Target Price	4.81
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-60.88%	Payout	-	Rel Volume	0.69	Prev Close	2.15
Sales Surprise	-44.99%	EPS Surprise	-59.80%	Sales Q/Q	-58.42%	Earnings	May 14 AMC	Avg Volume	95.77K	Price	2.34
SMA20	8.08%	SMA50	11.66%	SMA200	7.93%	Trades		Volume	66,280	Change	8.84%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-16-21	Initiated	Stephens	Overweight	$8

Apr-25-24 08:00AM	Genasys Inc. Schedules Fiscal Second Quarter 2024 Financial Results and Conference Call for May 14, 2024 (GlobeNewswire)
Mar-26-24 08:00AM	Genasys Partners in European Union-Funded Project to Revolutionize Public Warning (GlobeNewswire) +11.42%
Feb-15-24 11:07AM	Genasys Inc. (NASDAQ:GNSS) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-13-24 04:45PM	Genasys Inc. Reports Fiscal First Quarter 2024 Financial Results (GlobeNewswire)
08:00AM	State of Utah Department of Corrections Selects Genasys Protect CONNECT for Secure Communications (GlobeNewswire)
07:00AM	Loading…
Feb-12-24 07:00AM	Genasys Awarded Critical Infrastructure Project to Engineer, Procure and Build Emergency Warning System for 37 Dams Across the Island of Puerto Rico (GlobeNewswire) +16.40%
Jan-23-24 08:00AM	Genasys Inc. Schedules Fiscal First Quarter 2024 Financial Results and Conference Call for February 13, 2024 (GlobeNewswire)
Jan-18-24 08:00AM	Los Angeles County Awards 5 Year Contract to Genasys for Evacuation Management Solution (GlobeNewswire) +8.33%
Jan-04-24 09:30AM	iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024 (ACCESSWIRE) -6.67%
08:00AM	Genasys to Present at Leading Investor Conferences (GlobeNewswire)
Dec-08-23 08:21AM	Genasys Inc. (NASDAQ:GNSS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Dec-07-23 09:53PM	GNSS Stock Earnings: Genasys Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:12PM	Genasys Inc. Reports Fiscal Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire)
Dec-06-23 08:00AM	Genasys Announces New Critical Infrastructure Protection Orders for the U.S. Energy Sector (GlobeNewswire)
Dec-05-23 08:00AM	Middle Eastern Defense Force Selects Genasys to Improve Maritime Safety (GlobeNewswire)
07:00AM	Loading…
Nov-22-23 07:00AM	Genasys Inc. Schedules Fiscal Year 2023 Financial Results and Conference Call for December 7, 2023 (GlobeNewswire)
Nov-09-23 08:00AM	Genasys Partners With Ladris to Provide AI Powered Evacuation Modeling (GlobeNewswire)
Oct-23-23 08:00AM	New Hampshire Selects Genasys to Improve Public Safety Communication (GlobeNewswire)
Oct-10-23 08:00AM	Genasys Inc. Announces $1M U.S. Army CROWS-AHD Prototype Contract (GlobeNewswire)
Oct-05-23 10:43AM	Genasys (GNSS) Enhances Emergency Response With Evertel Buyout (Zacks)
Oct-04-23 04:05PM	Genasys Completes Acquisition of Evertel (GlobeNewswire)
04:05PM	Genasys Announces Closing of $10 Million Public Offering of Common Stock (GlobeNewswire)
Sep-28-23 10:00AM	Tablet Command and Genasys Partner on Real-Time Evacuation Insights for Fire Agencies Nationwide (GlobeNewswire) -19.53%
08:44AM	Genasys Announces Pricing of $10 Million Public Offering of Common Stock (GlobeNewswire)
Sep-27-23 04:05PM	Genasys Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-26-23 05:01PM	Genasys Signs Definitive Agreement to Acquire Evertel (GlobeNewswire)
Sep-18-23 07:00AM	Genasys Comments on Expanding Pipeline for Protective Communications (GlobeNewswire)
Sep-07-23 08:00AM	US Military Strengthens Commitment to Genasys Systems (GlobeNewswire)
Sep-06-23 08:00AM	City of Boston Selects Genasys Protect to Power Its Preparedness and Emergency Communication (GlobeNewswire)
Sep-05-23 08:00AM	Vietnam Ministry of Defense Expands Genasys Contract for Naval Frigates (GlobeNewswire)
04:05PM	Loading…
Aug-10-23 04:05PM	Genasys Inc. Reports Fiscal Third Quarter 2023 Financial Results (GlobeNewswire) +13.31%
Aug-07-23 08:00AM	Critical Communications Leader Genasys Rebrands and Launches World's First Protective Communications Platform (GlobeNewswire)
Jul-27-23 08:00AM	Boulder County Selects Genasys Inc. to Expand Emergency Communication Coverage in Colorado (GlobeNewswire)
Jul-26-23 02:00PM	Genasys Inc. Schedules Fiscal Third Quarter 2023 Financial Results and Conference Call for August 10, 2023 (GlobeNewswire)
Jun-06-23 08:00AM	Protective Communications Leader Genasys Announces $10.7M U.S. Army Follow-On Award (GlobeNewswire)
May-24-23 08:30AM	Genasys Inc. to Present at LD Micro Invitational XIII (GlobeNewswire)
May-08-23 04:22PM	Genasys Inc. Reports Fiscal Second Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 08:30AM	Santa Cruz and San Benito Counties Select Genasys to Power Public Safety Alerts and Notifications (GlobeNewswire)
Apr-24-23 08:45AM	Genasys Inc. Schedules Fiscal Second Quarter 2023 Financial Results and Conference Call for May 8, 2023 (GlobeNewswire)
08:00AM	Genasys Inc. to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-04-23 08:30AM	Genasys Inc. Receives Mass Notification System Order for Large Entertainment Venue (GlobeNewswire)
Mar-30-23 08:30AM	Genasys Inc. Expands Critical Communications Coverage in San Diego County with New Zonehaven Contract (GlobeNewswire)
Feb-16-23 08:30AM	Genasys Inc. to Present at Best Ideas Virtual Investor Conference (GlobeNewswire)
Feb-09-23 04:34PM	Genasys Inc. Awarded Contract to Provide Critical Notifications to Aramco (GlobeNewswire)
04:10PM	Genasys Inc. Reports Fiscal First Quarter 2023 Financial Results (GlobeNewswire)
Feb-01-23 08:30AM	Genasys Inc. Announces New and Follow-On Public Safety Emergency Warning Systems Orders (GlobeNewswire)
Jan-26-23 08:30AM	Genasys Inc. Receives $1.6 Million International Bird & Wildlife Preservation Order (GlobeNewswire)
Jan-24-23 08:30AM	Genasys Inc. Schedules Fiscal First Quarter 2023 Financial Results and Conference Call for February 9, 2023 (GlobeNewswire)
Jan-04-23 08:30AM	Genasys Inc. Secures Emergency Management and Evacuation Software Services Contract from Utah Counties (GlobeNewswire) +6.94%
Dec-13-22 08:30AM	Genasys Inc. Announces New Zonehaven and Genasys Emergency Management Contract with Monterey County, CA (GlobeNewswire)
Dec-08-22 08:30AM	Genasys Inc. to Participate in the Imperial Capital 2022 Security Investor Conference (GlobeNewswire)
Dec-02-22 05:23AM	Genasys Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-30-22 04:05PM	Genasys Inc. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Nov-17-22 08:30AM	Genasys Inc. Adds Four More California Counties to Zonehaven Evacuation Management Contracts (GlobeNewswire)
Nov-10-22 08:00AM	Genasys Inc. Signs Zonehaven SaaS Contract to Expand Critical Communications Coverage in Riverside County, California (GlobeNewswire)
Nov-07-22 08:30AM	Genasys Inc. Schedules Fiscal Year 2022 Financial Results and Conference Call for November 30, 2022 (GlobeNewswire)
Nov-02-22 08:00AM	Genasys Inc. Awarded Emergency Management Contract from San Diego County, California (GlobeNewswire)
Oct-25-22 08:30AM	Genasys Inc. Receives Follow-On International Wildlife Preservation Orders (GlobeNewswire)
Oct-20-22 08:30AM	Genasys Inc. to Participate in the Stephens Annual Investment Conference (GlobeNewswire)
Oct-13-22 12:00AM	Genasys Inc. Selected to Exhibit at Smart City Expo World Congress 2022 by the U.S. Commercial Service (GlobeNewswire)
Oct-11-22 12:00AM	Genasys Joins ASELF, The Leading Firefighting Association in Spain (GlobeNewswire)
Oct-05-22 08:30AM	Genasys Inc. Announces SaaS Contracts from Utility Companies in California, Florida and Washington (GlobeNewswire)
Sep-27-22 08:00AM	Genasys Inc. Announces Multi-Year Enterprise Software Services Contract from Global Automaker (GlobeNewswire) -5.82%
Sep-21-22 08:30AM	Genasys Inc. Receives New Emergency Management Software Services Contract from the West All Hazards Region of Colorado (GlobeNewswire) +5.02%
Sep-19-22 08:30AM	Genasys Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.61%
Sep-07-22 08:30AM	Genasys Inc. Announces New Emergency Management and Zonehaven Software Services Contracts (GlobeNewswire) +6.76%
Sep-06-22 02:00AM	Genasys Exhibiting In Person and Virtually at BCI World Hybrid 2022 (GlobeNewswire) -6.02%
Aug-11-22 04:05PM	Genasys Inc. Reports Fiscal Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-10-22 08:30AM	Genasys Inc. to Ring the Nasdaq Closing Bell Today (GlobeNewswire)
Aug-09-22 08:30AM	Genasys Inc. Receives $2.2 Million LRAD® Order for Commercial Security (GlobeNewswire)
Aug-04-22 08:30AM	Genasys Inc. Partners with Boston Red Sox to Deliver Critical Communications at Fenway Park (GlobeNewswire)
Aug-02-22 08:00AM	Genasys Inc. Appoints Dennis Walsh as Chief Revenue Officer (GlobeNewswire)
Jul-27-22 08:30AM	Genasys Inc. Schedules Fiscal Third Quarter 2022 Financial Results and Conference Call for August 11, 2022 (GlobeNewswire) +5.25%
Jul-26-22 08:00AM	Genasys Inc. Expands Zonehaven Software Services in Santa Clara County, California (GlobeNewswire)
Jun-28-22 11:30AM	Genasys Inc. Receives $15.7 Million U.S. Army Program of Record Follow-On Order (GlobeNewswire)
Jun-15-22 08:30AM	Genasys Inc. Announces New Government and Enterprise GEM Software Contracts (GlobeNewswire)
May-30-22 12:00PM	All You Need to Know About Genasys (GNSS) Rating Upgrade to Strong Buy (Zacks)
May-26-22 08:30AM	Genasys Inc. to Present at the LD Micro Invitational XII Investor Conference on June 8, 2022 (GlobeNewswire) +13.80%
May-25-22 08:30AM	Genasys Inc. Evacuation Management and Critical Communications Keeping California Residents Safe During Year-Round Fire Season (GlobeNewswire) +5.84%
May-19-22 08:30AM	Genasys Inc. Receives $1.5 Million in LRAD Foreign Military Sales and International Defense Orders (GlobeNewswire)
May-09-22 04:05PM	Genasys Inc. Reports Fiscal Second Quarter 2022 Financial Results (GlobeNewswire) +14.02%
May-03-22 09:05AM	Could The Genasys Inc. (NASDAQ:GNSS) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Apr-28-22 08:00AM	Genasys Inc. Announces New Zonehaven SaaS Contracts in California and Oregon (GlobeNewswire)
Apr-21-22 08:00AM	Genasys Inc. Announces Critical Communication and Evacuation SaaS Contracts in Six U.S. States (GlobeNewswire) +11.64%
Apr-19-22 08:30AM	Genasys Inc. Announces Next Generation Integrated Mass Notification System (IMNS) Installations and Order (GlobeNewswire)
Apr-14-22 08:30AM	Genasys Inc. Schedules Fiscal Second Quarter 2022 Financial Results and Conference Call for May 9, 2022 (GlobeNewswire)
Apr-12-22 08:30AM	Genasys Inc. Initiates Shipments of New LRAD® 950NXT The World's Most Advanced Acoustic Hailing Device (GlobeNewswire)
Mar-21-22 11:59AM	Those who invested in Genasys (NASDAQ:GNSS) five years ago are up 101% (Simply Wall St.)
08:30AM	Genasys Inc. Awarded Supplier Contract from Sourcewell (GlobeNewswire)
Feb-07-22 04:05PM	Genasys Inc. Reports Fiscal First Quarter 2022 Financial Results (GlobeNewswire)
Feb-03-22 08:00AM	Genasys Inc. Announces Zonehaven SaaS Contract with Los Angeles County (GlobeNewswire)
Feb-02-22 08:30AM	Genasys Inc. Announces Multiple Critical Communications Software Services Contracts in Texas (GlobeNewswire)
Jan-31-22 03:00PM	Analysts Estimate Genasys (GNSS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-28-22 10:07AM	36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 (ACCESSWIRE)
Jan-26-22 08:00AM	Genasys Inc. Selected to Power Nationwide Public Warning System for Slovenia (GlobeNewswire)
Jan-20-22 06:18AM	Estimating The Fair Value Of Genasys Inc. (NASDAQ:GNSS) (Simply Wall St.)
Jan-19-22 08:00AM	Genasys Inc. Awarded $1.97 Million Public Safety Mass Notification and Emergency Warning Systems Contract from The City of Berkeley, CA (GlobeNewswire)
Jan-18-22 08:30AM	Genasys Inc. Schedules Fiscal First Quarter 2022 Financial Results and Conference Call for February 7, 2022 (GlobeNewswire)
Jan-14-22 09:38AM	Mesirow Financial Investment Management, Inc. ... (GuruFocus.com)
Jan-13-22 08:30AM	Genasys Inc. to Participate in Best Ideas Virtual Investor Conference (GlobeNewswire)

Genasys, Inc. engages in the provision of critical communications hardware and software solutions and a multi-channel approach to deliver geo-targeted alerts, notifications, instructions, and information before, during, and after public safety threats and critical business events. Its communications platform includes Genasys Emergency Management (GEM) applications, National Emergency Warning Systems (NEWS), and LRAD long-range voice broadcast systems. The firm operates through the following segments: Hardware and Software. The company was founded by Elwood G. Norris in 1980 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anchin Scott L	Director	Dec 14 '23	Buy	1.85	20,000	37,000	268,152	Dec 15 11:59 AM
Anchin Scott L	Director	Dec 13 '23	Buy	1.73	8,000	13,840	248,152	Dec 15 11:59 AM
Osgood Richard Hoe III	Director	Dec 12 '23	Buy	1.69	10,000	16,910	467,883	Dec 13 05:25 PM
Osgood Richard Hoe III	Director	Oct 02 '23	Buy	2.00	50,000	100,000	457,883	Oct 10 11:35 AM
AWM Investment Company, Inc.	10% Owner	Sep 28 '23	Buy	2.00	1,400,000	2,800,000	5,749,544	Oct 02 04:35 PM
Danforth Richard	CEO	Jun 07 '23	Option Exercise	1.99	150,753	299,998	194,692	Jun 09 04:40 PM
Danforth Richard	CEO	May 26 '23	Option Exercise	1.99	786,747	1,565,627	793,247	May 31 04:20 PM
Anchin Scott L	Director	May 12 '23	Buy	2.40	5,000	12,000	2,500	May 15 01:21 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LAB

Standard BioTools Inc

TVTX

Travere Therapeutics Inc

GNSS

Genasys Inc

Upgrade your FINVIZ experience